10-K: Bicycle Therapeutics Reprioritizes Pipeline, Cuts Workforce Amid Rising Losses

Bicycle Therapeutics reported increased net losses in 2025 and announced a strategic reprioritization of its clinical pipeline, including discontinuing certain trials and a 30% workforce reduction, to focus on next-generation therapeutics.

Summary

• Net loss increased to $219.0 million for the year ended December 31, 2025, compared to $169.0 million in 2024.
• Accumulated deficit reached $899.8 million as of December 31, 2025.
• Collaboration revenue increased to $72.586 million in 2025, up from $35.275 million in 2024, primarily due to revenue recognition from the termination of agreements with Novartis ($38.8 million) and Bayer ($5.5 million).
• Research and development expenses rose to $240.283 million in 2025 from $172.966 million in 2024, driven by increased clinical program expenses for zelenectide pevedotin and advancing the Bicycle radioligand pipeline.
• General and administrative expenses increased to $79.368 million in 2025 from $72.181 million in 2024.
• A strategic reprioritization of the clinical portfolio was announced in March 2026, focusing on nuzefatide pevedotin and next-generation Bicycle conjugates (BRC molecules).
• The Phase II/III Duravelo-2 registrational trial for zelenectide pevedotin will be converted to a randomized Phase II trial and the program deprioritized for internal development.
• Phase I/II clinical trials evaluating zelenectide pevedotin in NECTIN4 amplified advanced breast cancer and non-small cell lung cancer will be discontinued.
• A proposed workforce reduction of approximately 30% was announced in March 2026, expected to reduce annual operating expenses by approximately 50% and incur $8.0 million in severance charges.
• BT7480 (Bicycle Tumor-Targeted Immune Cell Agonist) will no longer be developed internally after reporting H1 2026 data, with partnership opportunities to be explored.
• Cash and cash equivalents were $628.1 million as of December 31, 2025, expected to fund operating expenses and capital expenditure requirements for at least 12 months from the filing date (March 17, 2026).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for Bicycle Therapeutics, marked by increasing net losses, significant pipeline reprioritization, and workforce reductions, despite some promising clinical data for remaining programs and strategic efforts to secure radioisotope supply. The terminations of multiple collaboration agreements and the need for substantial future funding underscore the financial pressures and execution risks.

Positives

• Collaboration revenue significantly increased to $72.586 million in 2025, largely due to the recognition of remaining revenue from terminated agreements.
• Nuzefatide pevedotin (EphA2 BDC) showed promising Phase I/II clinical results in advanced solid tumors, with a 34% Overall Response Rate (ORR) in metastatic urothelial cancer and a 45% ORR in the expansion cohort (6.5 mg/m2 every two weeks).
• Nuzefatide pevedotin demonstrated a differentiated safety profile, with no hemorrhage or hematological toxicities and low rates of treatment-related peripheral neuropathy (TRPN), contrasting with safety concerns seen in other EphA2-targeting ADCs.
• Zelenectide pevedotin (Nectin-4 BDC) monotherapy achieved a 45% ORR in metastatic urothelial cancer patients (not previously treated with enfortumab vedotin), with a median duration of response of 11.1 months.
• Zelenectide pevedotin in combination with pembrolizumab showed a 65% ORR in previously untreated cisplatin-ineligible metastatic urothelial cancer patients.
• Zelenectide pevedotin exhibited a differentiated safety profile with no Grade 3 or higher peripheral neuropathy, skin reactions, or eye disorders.
• BT1702 (MT1-MMP BRC) demonstrated a favorable biodistribution profile and reduced tumor burden in preclinical models, with IND-enabling activities ongoing.
• Successful first human imaging data for MT1-MMP and EphA2 Bicycle Imaging Agents (BIA molecules) validate these targets and the potential of Bicycle molecules for targeted radionuclide therapy.
• Established a potentially sustainable radioisotope supply chain through agreements with Eckert & Ziegler, UK Nuclear Decommissioning Authority (UKNDA) for reprocessed uranium, and UK National Nuclear Laboratory (UKNNL) for thorium-228 extraction to produce lead-212.
• ION826, an investigational siRNA medicine incorporating a TfR1 Bicycle molecule under the Ionis collaboration, entered Phase I development in December 2025 for PLN-R14del dilated cardiomyopathy.
• The strategic reprioritization and workforce reduction are expected to reduce annual operating expenses by approximately 50%, aiming for greater financial efficiency.
• The company maintains a strong intellectual property portfolio with 536 patents and 412 pending applications as of December 31, 2025.

Negatives

• Net loss increased to $219.0 million in 2025 from $169.0 million in 2024, and the accumulated deficit reached $899.8 million, indicating continued significant operating losses.
• The strategic reprioritization announced in March 2026 involves deprioritizing zelenectide pevedotin for internal development and converting its Phase II/III registrational trial to a randomized Phase II trial, signaling a setback for this advanced program.
• Phase I/II clinical trials for zelenectide pevedotin in NECTIN4 amplified advanced breast cancer and non-small cell lung cancer are being discontinued, closing further enrollment.
• Internal development of BT7480 will cease after H1 2026 data, with the company seeking partnership opportunities, indicating a shift away from wholly-owned development for this program.
• Collaboration agreements with Genentech (effective August 2025) and Novartis (effective February 2026) were terminated, and one initial target program with Bayer was also terminated (effective January 2026), reducing future potential collaboration revenue streams.
• Workforce reductions in August 2025 ($5.3 million in severance charges) and an expected 30% reduction in March 2026 ($8.0 million in severance charges) highlight significant restructuring and potential impacts on employee morale and institutional knowledge.
• Research and development expenses increased by $67.3 million in 2025, contributing to higher operating losses.
• Interest and other income decreased by $5.8 million in 2025, partly due to lower average interest rates.
• The UK trademark application for TICA was successfully opposed in the U.K., Japan, and the EU, and the U.S. application was abandoned, impacting brand recognition for this program.

Risks

• The company has a history of significant operating losses and expects to incur increasing losses, with no assurance of achieving or maintaining profitability.
• Substantial additional funding is required, and the inability to raise capital on acceptable terms could force delays, reductions, or elimination of product discovery, development, or commercialization efforts.
• Raising additional capital may dilute existing shareholders, restrict operations, or require relinquishing valuable rights.
• Future success is heavily dependent on the success of internal BDC and BRC programs, which may not successfully complete clinical trials, receive regulatory approval, or be commercialized.
• Product candidates represent a new category of medicines (Bicycle molecules) and may face heightened regulatory scrutiny due to limited prior experience by regulatory authorities.
• Difficulty in enrolling patients in clinical trials could delay or prevent progression of product candidates.
• Results from preclinical studies and early clinical trials may not be predictive of success in future, larger clinical trials.
• Current or future product candidates may cause undesirable side effects, potentially halting clinical development, preventing marketing approval, or limiting commercial potential.
• The company may be delayed or unsuccessful in identifying or discovering additional product candidates to expand its pipeline.
• Limited resources may be expended on development strategies or product candidates that ultimately prove less profitable or less likely to succeed.
• Failure to successfully validate, develop, and obtain regulatory approval for companion diagnostics could harm the drug development strategy.
• Uncertainty in obtaining and maintaining adequate insurance coverage and reimbursement for any approved products could limit marketability and revenue generation.
• Healthcare legislative reform measures (e.g., OBBBA, Medicare Drug Price Negotiation Program, EU HTA Regulation) may negatively impact business and results of operations by limiting payments or increasing costs.
• The company and its third-party partners are subject to stringent and evolving data privacy and security laws (e.g., HIPAA, CCPA, EU GDPR, UK GDPR, MHMD, BIOSECURE Act); non-compliance could lead to investigations, litigation, fines, and business disruption.
• Reliance on third parties (clinical investigators, CROs, CMOs) for clinical trials and manufacturing increases the risk of delays, insufficient supplies, or quality issues.
• Inability to obtain and maintain patent and other intellectual property protection, or if the scope of protection is insufficient, could allow competitors to commercialize similar products.
• Risk of intellectual property infringement lawsuits from third parties, which could be costly and delay development or commercialization.
• Claims challenging the inventorship or ownership of patents and other intellectual property could result in loss of valuable rights.
• Non-compliance with procedural requirements for patent agencies could lead to reduction or elimination of patent protection.
• Changes in patent law in the U.S. and other jurisdictions could diminish the value of patents.
• Inability to protect intellectual property rights throughout the world due to varying legal systems and enforcement.
• Workforce reductions may lead to unintended consequences such as loss of institutional knowledge, decreased employee morale, attrition beyond planned reductions, and difficulty pursuing new opportunities.
• Future success depends on the ability to attract, retain, and motivate qualified personnel, which is challenging given intense industry competition.
• Risk of misconduct or improper activities by employees, contractors, consultants, collaborators, and CROs, leading to significant liability and reputational harm.
• Difficulties in managing growth, including expanding operations and recruiting personnel, could disrupt operations.
• The market price of ADSs is highly volatile and may be influenced by numerous factors unrelated to operating performance.
• Exposure to economic, political, regulatory, and other risks associated with international operations, including tariffs, sanctions, trade barriers, and foreign currency exchange rate fluctuations.
• The dual-class share structure may limit the ability of certain shareholders to influence corporate matters.
• Substantial future sales or issuances of shares or equity-related securities could adversely affect ADS price and dilute existing shareholders.
• No anticipated cash dividends; capital appreciation is the sole source of gains for ADS holders.
• Claims of U.S. civil liabilities may not be enforceable against the company due to its incorporation under English law.
• Potential adverse U.S. federal income tax consequences to U.S. holders if the company is classified as a Passive Foreign Investment Company (PFIC).
• May be unable to fully utilize net operating loss and tax credit carryforwards or benefit from favorable U.K. tax legislation.
• Future changes to tax laws could materially adversely affect the company and reduce net returns to shareholders.
• Tax authorities may disagree with tax positions, resulting in unanticipated costs or non-realization of expected benefits.
• Provisions in the U.K. City Code on Takeovers and Mergers may not apply, limiting certain takeover offer protections for shareholders.
• Rights of shareholders may differ from those typically offered to shareholders of a U.S. corporation.
• Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reporting or fraud.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Risk of securities class action litigation following declines in share price.
• Inaccurate or unfavorable research by securities or industry analysts could cause ADS price and trading volume to decline.

Future Outlook

The company expects its expenses and capital requirements to decrease in the near term due to cost-saving initiatives and strategic reprioritization, but anticipates they will increase over the longer term with continued clinical development of product candidates like nuzefatide pevedotin and BT1702, identification of new candidates, and commercialization efforts. The first company-sponsored radioligand clinical trial for BT1702 is planned for 2027. Data presentations for nuzefatide pevedotin in combination with nivolumab and for pancreatic ductal adenocarcinoma, as well as longer-term follow-up data for zelenectide pevedotin, are expected in the first half of 2026. The company will explore partnership opportunities for BT7480 after reporting combination data in the first half of 2026. Substantial additional funding will be required to support continuing operations and growth.

Management Comments

• "Our mission is to become a leading pharmaceutical company by pioneering Bicycle molecules as a novel therapeutic modality to treat diseases that are inadequately addressed with existing treatment modalities."
• "We believe Bicycle molecules are an ideal vehicle to deliver small molecule payloads to tumors."
• "We believe the properties of our BDC molecules may address the challenges associated with ADCs and therefore that our approach has the potential to offer substantial benefits."
• "Collectively, we believe this bespoke set of arrangements is designed to support the potential discovery, development and commercial supply of a portfolio of BRC molecules containing 212Pb."
• "Altogether, we believe these data validate the potential of MT1-MMP as a novel target in the treatment of cancer, demonstrate the translatability of Bicycle radioligand preclinical data and highlight the potential of Bicycle molecules for targeted radionuclide therapy."
• "We believe the differentiated properties of Bicycle molecules may allow us to develop molecules with a pharmacodynamically distinct and improved profile over existing therapies."
• "We expect that our expenses and capital requirements will decrease in the near term as a result of our cost saving initiatives and our strategic reprioritization announced in March 2026."
• "We believe that our existing cash and cash equivalents of $628.1 million as of December 31, 2025, will enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from the date of filing of this Annual Report."

Industry Context

StockSavvy.ai notes that Bicycle Therapeutics operates in the highly competitive biotechnology and pharmaceutical industries, characterized by rapidly advancing technologies and intense competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies. The company's focus on novel Bicycle molecules as a therapeutic modality aims to address limitations of existing treatments like Antibody Drug Conjugates (ADCs), particularly regarding tumor penetration, systemic half-life, and internalization requirements. The strategic reprioritization and workforce reduction reflect a common industry trend of optimizing pipelines and managing costs in response to clinical trial outcomes and market dynamics, especially for early-stage companies with significant R&D expenditures. The company's efforts in radiopharmaceuticals align with a growing interest in targeted alpha therapy, but also face manufacturing and supply chain challenges common in this specialized field.

Comparison to Industry Standards

• Nuzefatide pevedotin's 34% Overall Response Rate (ORR) in metastatic urothelial cancer and 45% ORR in the expansion cohort (6.5 mg/m2 every two weeks) are stated to be comparable to published rates for existing standards of care, but with a differentiated safety profile (no hemorrhage or hematological toxicities, low TRPN) which is a significant improvement over EphA2-targeting ADCs like MEDI-547, which saw bleeding events and liver toxicity.
• Zelenectide pevedotin's 45% ORR in metastatic urothelial cancer (not previously treated with enfortumab vedotin) and 65% ORR in combination with pembrolizumab for cisplatin-ineligible patients are presented in the context of enfortumab vedotin's FDA approvals for similar indications, suggesting a competitive efficacy profile with a differentiated safety profile (no Grade 3+ peripheral neuropathy, skin reactions, or eye disorders) compared to existing Nectin-4 ADCs.
• Bicycle molecules are positioned as a unique therapeutic class, combining the pharmacological properties of biologics with the manufacturing and pharmacokinetic advantages of small molecules, including lower production costs and simpler manufacturing compared to ADCs.
• Preclinical studies showed Bicycle molecules penetrate tumors more rapidly and exhibit increased penetration to poorly perfused regions compared to comparator antibodies, and achieve 10 times higher tumor cytotoxin levels than plasma levels, suggesting superior tumor delivery compared to traditional antibody-based approaches.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings.

Related Party Transactions

• Consultancy services provided by Stone Atlanta Estates LLC (associated with former Chairman Pierre Legault) totaling $0.1 million in 2025, $0.3 million in 2024, and $0.2 million in 2023.
• Entities affiliated with Baker Bros. Advisors LP (Baker Entities), whose managing member is Felix J. Baker (Chairman of the board), purchased an aggregate of 17,114,846 non-voting ordinary shares for $366.6 million in a private placement in May 2024.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises, continued volatility in ADS price, and limited influence due to the dual-class share structure. No cash dividends are anticipated, making capital appreciation the sole source of gains.
• Employees are impacted by workforce reductions (30% in March 2026, previous in August 2025) leading to severance charges, potential loss of institutional knowledge, decreased morale, and challenges in attracting and retaining qualified personnel.
• Patients may see accelerated development of nuzefatide pevedotin and BRC molecules due to strategic reprioritization, but the deprioritization and discontinuation of other programs (zelenectide pevedotin in certain indications, BT7480 internally) could limit future treatment options.
• Collaborators are affected by the termination of agreements with Genentech, Novartis, and one Bayer target program, which alters existing partnerships and potential future revenue streams for the company.

Next Steps

• Continue development and clinical trials for nuzefatide pevedotin and BT1702.
• Present data for nuzefatide pevedotin in combination with nivolumab in patients with metastatic urothelial cancer at a scientific conference in the first half of 2026.
• Present additional information regarding nuzefatide pevedotin in recurrent metastatic pancreatic ductal adenocarcinoma at a scientific conference in the first half of 2026.
• Present longer-term follow-up data for zelenectide pevedotin monotherapy in late-line metastatic urothelial cancer and additional data for zelenectide pevedotin in combination with pembrolizumab in first-line cisplatin-ineligible and cisplatin-eligible metastatic urothelial cancer at a scientific conference in the first half of 2026.
• Explore partnership opportunities for BT7480 after reporting combination data in the first half of 2026.
• Initiate the first company-sponsored radioligand clinical trial for BT1702 in 2027.
• Advance discovery programs into clinical development, including expanding the pipeline of Bicycle radioligand molecules and next-generation BDC molecules.
• Complete the proposed workforce reduction of approximately 30% by the end of 2026.
• Evaluate next steps for zelenectide pevedotin following preliminary feedback from regulatory agencies.
• Continue IND-enabling activities for BT1702.
• Seek marketing and regulatory approvals for any product candidates that successfully complete clinical trials.
• Build in-house process development and analytical capabilities and continue to discover and develop additional product candidates.
• Expand research and development infrastructure, including hiring and retaining additional personnel.
• Acquire or in-license other products and technologies.
• Add operational, financial, and management information systems and personnel.
• Maintain, expand, and protect the intellectual property portfolio.

Key Dates

Recommendation

The company faces significant financial challenges, evidenced by increasing net losses and a substantial accumulated deficit. The strategic reprioritization, while aiming for efficiency, involves deprioritizing and discontinuing several clinical programs (zelenectide pevedotin in certain indications, BT7480 internally) and the termination of key collaboration agreements (Genentech, Novartis, one Bayer target). These actions, coupled with a 30% workforce reduction, signal a contraction in the company's broad pipeline strategy and raise concerns about future revenue generation and the ability to secure necessary funding without significant dilution. While some clinical data are promising, the overall financial health and pipeline adjustments suggest a high-risk investment profile with near-term headwinds.

Keywords

Oncology, Bicycle molecules, Drug Conjugates, Radioconjugates, EphA2, Nectin-4, MT1-MMP, Clinical Trials, Biotechnology, Pharmaceutical, Cancer Therapy, R&D, SEC Filing, 10-K, Nuzefatide pevedotin, Zelenectide pevedotin, BT1702, BT7480, Workforce Reduction, Pipeline Reprioritization